Nona Biosciences Appoints Dr. Di Hong as CEO to Advance Antibody Discovery Platform
核心洞察
Nona Biosciences (搜索) has appointed Dr. Di Hong (搜索) as Chief Executive Officer to lead the company's next phase of growth in antibody discovery and development.
The company has expanded its proprietary Harbour Mice (搜索)® technology platform into HCAb PLUS (搜索)™, integrating bispecific antibodies (搜索), ADCs, cell therapies, and AI technologies.
Dr. Hong brings over 20 years of leadership experience across biopharma, CRO, and investment sectors, most recently serving as CEO of Gaoyue Group (搜索).
Nona Biosciences (搜索), a global biotechnology company specializing in integrated antibody discovery solutions, announced the appointment of Dr. Di Hong (搜索) as Chief Executive Officer on October 14, 2025. Dr. Hong will be based in Shanghai and report directly to Dr. Jingsong Wang (搜索), Chairman of Nona Biosciences, marking a pivotal step in the company's strategy to accelerate innovation in antibody discovery and development.
Technology Platform Evolution
The leadership transition comes as Nona has expanded its capabilities from its proprietary Harbour Mice (搜索)® technology platform into HCAb PLUS (搜索)™, described as the 2.0 version of Harbour Mice®. This next-generation platform integrates cutting-edge technologies including bispecific and multispecific antibodies (搜索), antibody-drug conjugates (搜索) (ADCs), cell therapies, RNA-enabled therapeutics, and artificial intelligence to reshape the drug discovery paradigm and foster a global collaborative ecosystem.
The Harbour Mice (搜索)® platform generates fully human monoclonal antibodies (搜索) in both classical two light and two heavy chain (H2L2) format and heavy chain-only (HCAb) format. The HCAb Harbour Mice® represents the world's first fully human HCAb transgenic mouse with clinical validation, offering exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system.
Strategic Leadership Vision
In his new role, Dr. Hong will lead Nona's next stage of growth by strengthening its highly efficient service system, advancing technology innovation, integrating AI and external investment, and further evolving the business model into a "Service Plus" ecosystem-powered platform. This direction is designed to enhance strategic agility and position the company for long-term leadership in the global biopharmaceutical industry.
Dr. Hong brings over 20 years of leadership experience spanning science, operations, and strategy. Most recently, as CEO of Gaoyue Group (搜索), the life science infrastructure platform of Hillhouse (搜索), he built a national life science network and established a "Lab-to-Market" ecosystem. His career includes senior roles at Hua Medicine (搜索), Bioduro-Sundia (搜索), Amgen, Eli Lilly, and Roche in China, blending global and local expertise across biopharma, CRO, and investment sectors.
Comprehensive Technology Integration
Nona Biosciences (搜索) has developed an integrated platform that combines Harbour Mice (搜索)®, single-B cell screening technology, NonaCarFx (搜索)™ (a direct CAR-function-based screening platform), Hu-mAtrIx (搜索)™ (an AI-driven drug discovery platform), Modalities-on-Demand™ (a next-generation modalities solution), and end-to-end preclinical drug development services. This comprehensive approach supports the company's "Idea to IND" service model, ranging from target validation and antibody discovery through preclinical research.
The company's integrated antibody and antibody-related discovery services cover a broad range of modalities, from antigen preparation and animal immunization to single B cell screening, antibody lead generation and engineering, developability assessment, and pharmacological evaluation.
Leadership Perspectives
Dr. Jingsong Wang (搜索), Chairman of Nona Biosciences (搜索), expressed confidence in the appointment: "Dr. Hong's broad leadership experience across biopharma, CRO, and investment, along with his track record in building innovative ecosystems, make him exceptionally well-suited to lead Nona into its next phase of growth. I am confident that under his leadership, Nona team will further strengthen our technology platforms, expand global partnerships, and advance our vision of becoming a long-term leader in biologics innovation."
Dr. Hong emphasized his commitment to expanding the company's innovation ecosystem: "I look forward to leading Nona Biosciences (搜索)' entrepreneurial team to explore more cutting-edge technology platforms, expand broader global cooperation, and build a more open innovation ecosystem. Nona Biosciences will act as a leader of biopharmaceutical innovation and continuously bring more valuable products and services to patients and clients."
Dr. Hong holds a Doctor of Business Administration from Université Nice Sophia Antipolis, as well as Master's and Bachelor's degrees in Chemistry from Zhejiang University.